Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.66 |
| ▸ | CTSS | P25774 | 1/20 | 0.66 |
| ▸ | CTSK | P43235 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | CCKBR | P32239 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TACR1 | P25103 | 2/20 | 0.59 |
| ▸ | REN | P00797 | 2/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | CCKAR | P32238 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30638852 | 0.91 | CTSL (0.70) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL31289556 | 0.91 | CTSL (0.66) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL2727403 | 0.87 | CTSL (0.71) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL7413708 | 0.87 | CTSL (0.71) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL2727405 | 0.87 | CTSL (0.71) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL30638853 | 0.87 | CTSL (0.71) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL19138339 | 0.86 | ECE1 (0.58) | CTSLMAPTACE | |
| SCHEMBL19138342 | 0.86 | ECE1 (0.58) | CTSLMAPTACE | |
| SCHEMBL29419169 | 0.86 | CTSL (0.67) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL23656831 | 0.85 | CTSL (0.74) | CTSLCTSSCTSKMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3916003-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | Naurex, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3171941-B1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-9994614-B2 | N-methyl-D-aspartate receptor modulators and methods of making and using same | NAUREX, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170210779-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2017-07-27 | — | — | US | disclosed |
| WO-2016014982-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210779-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | GRIN1, GRIN2A, GRIN3A | CTSL 3260/4885CTSS 3757/4885CTSK 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.